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Abstract 2,500 keystrokes 
Assisted reproductive technologies (ART) are widely used for both humans and domestic 
animals. In bovine species, in vitro embryo production is increasingly used and significant 30 
efforts are being made to optimize media and culture conditions. Phospholipase A2 (PLA2) are 
lipolytic enzymes that hydrolyze glycerophospholipids to produce free fatty acids and 
lysophospholipids that have been found to be critical for many biological processes. Mouse 
group X secreted PLA2 (mGX) is abundant in the male reproductive tract and its use during 
sperm capacitation has been shown to improve in vitro production of viable embryos in a mouse 35 
model. Here, we examined its effect in the bovine species, testing the impact of mGX on the 
three steps involved in in vitro production of preimplantation embryos: oocyte maturation, 
fertilization and preimplantation development. We found that incubating cumulus oocyte 
complexes (COC) or gametes with mGX resulted in increased blastocyst hatching and 
blastocyst production, respectively. The increases of embryo production induced by the 40 
phospholipase mGX   were not observed for the catalytically inactive mutant H48Q-mGX, 
suggesting that these effects require the enzymatic activity of mGX. We also tested bGIB, a 
bovine homolog of mGX. bGIB failed to improve blastocyst production, underlining the high 
specificity of mGX. In conclusion, the results presented show that the effects of mGX are not 
restricted to the mouse model and that it is potent in the bovine species as well. This result 45 
strengthens the potential of mGX as a “pro-fertility drug” for mammalian reproduction. 
 
1. Introduction 
Assisted reproductive technologies (ART) have greatly improved in recent decades, and are 
now widely used in humans and to manage animal reproduction [1-3]. In the bovine species, 50 
sperm cryopreservation and artificial insemination are currently the main ART used. However, 
in vitro embryo production has emerged as an interesting technology for specific cattle breeding 
objectives [4]. For instance in vitro embryo production maximizes the use of remarkable cows 
to produce more embryos with females presenting outstanding genetic background. Despite 
continuous efforts to improve in vitro blastocyst production efficiency, its yield remains low, 55 
and the proportion of oocytes reaching the blastocyst stage is barely 30 to 40%, which is half 
the yield obtained when combining ovarian stimulation with in vivo fertilization. Moreover, in 
vitro-produced blastocysts appear as being of lower quality than those produced in vivo [3, 5-
7]. 
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Optimization of culture media through supplementation with hormones, proteins and growth 60 
factors is one of the main current fields of research in in vitro blastocyst production; its main 
goal is to improve both efficiency of the technique and embryo quality [8-17]. 
In our search to identify new compounds which improve in vitro production of bovine 
blastocysts, we assessed the impact on in vitro blastocyst production of treating bovine gametes 
and early embryos with phospholipase A2 (PLA2). PLA2s form a superfamily of proteins 65 
hydrolyzing the sn2-ester bonds of glycerophospholipids, and are involved in many biological 
functions [18]. Three PLA2 subfamilies have been defined, based on calcium-sensitivity and 
their biological localization: two subfamilies are intracellular and calcium-independent (cPLA2 
and iPLA2) whereas the third subfamily is calcium-dependent and secreted (sPLA2) [19]. sPLA2 
is the largest subfamily, with 12 known isoforms. All PLA2 are involved in key steps of male 70 
and female reproductive physiology [20].  
In males, both sPLA2 and iPLA2 are expressed in the testes and accessory reproductive glands. 
They are involved in spermatogenesis, sperm maturation and sperm acrosome exocytosis. For 
instance, iPLA2 deficiency leads to abnormal sperm formation and a defective acrosome 
reaction [21, 22]. Mouse sPLA2 of group III (mGIII) is required for lipid remodeling during 75 
epididymal transit, and its deficiency results in severe epididymal maturation defects [23]. 
Previously, we showed that the mouse sPLA2 of group X (mGX) encoded by the Pla2g10 gene 
is present in the acrosome of murine sperm and is secreted during the acrosome reaction, 
whether induced or spontaneous  [24]. mGX induces changes in the lipid composition of the 
plasma membrane of the sperm, resulting in modified sperm mobility [25]. By a paracrine 80 
effect, mGX in conjunction with iPLA2 amplifies the acrosome reaction [22]. In mice, mGX 
has been shown to be involved in sperm fertilizing competence, and its absence (in knockout 
mice) results in a lower initial cleavage rate and a higher rate of early death in the early stages 
of in vitro development. These deleterious effects can be counteracted by adding recombinant 
mGX to the medium containing knockout sperm. Interestingly, treatment of normal sperm with 85 
recombinant mGX improves the production of viable murine embryos [24], opening a relevant 
field of investigation into the use of PLA2, and in particular mGX, in assisted reproduction in 
other species including bovine [26]. sPLA2 have an enzymatic activity (hydrolyzation) but also 
induce biological responses through mechanisms requiring their binding to specific membrane 
receptors [27]. In the mouse model we had demonstrated that the ability of mGX to increase 90 
viable embryo production was dependent on its enzymatic activity [24].  
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Compared to the mouse model, the in vitro production of bovine embryos usually requires an 
additional step corresponding to in vitro maturation of oocytes as the female gametes are 
obtained by puncture of immature follicles from ovaries. In this study, we therefore investigated 
the impact of adding recombinant mGX, a catalytically inactive mutant of mGX and the bovine 95 
group IB sPLA2 during in vitro oocyte maturation, fertilization and early preimplantation 
development of bovine embryos, on initial cleavage, production of blastocyst and blastocyst 
hatching rates.  
 
2. Materials and methods 100 
2.1.Semen collection 
Bull semen was collected by artificial vagina at the OrigenPlus technical center (L’Aigle, 
France). Ejaculate was diluted 1:1 in Optixcell (IMV technologies, L’Aigle, France) and after 
dilution, frozen and then stored in liquid nitrogen until required for in vitro fertilization. 
 105 
2.2. In vitro maturation of oocytes 
Bovine ovaries were collected at the slaughterhouse and transported in NaCl 0.9% 
supplemented with 0.2% of a solution containing 1% of kanamycin sulfate (Thermo Fisher 
Scientific, France) within 3 h in a container maintained at 35 °C. Cumulus-oocytes complexes 
(COCs) were recovered from 2-8 mm antral follicles by manual aspiration using a sterile 18-110 
gauge needle attached to a sterile 5 mL syringe containing collection medium (1% v/v PVA 
(Poly(Vinyl Alcohol)); 4.2 mM NaHCO3; 10 mM HEPES; 2 mM glutamine; 50 IU/mL 
penicillin; 50 µg/mL streptomycin, in M199 medium). Only grade 1 and 2 COCs were used for 
further processing [28]. Groups of around 30 COCs were matured in 4-well plates with 500 µL 
oocyte maturation medium per well for 24 h at 38.5 °C under 5% CO2 and saturating humidity. 115 
Oocyte maturation medium corresponded to a modified M199 medium, comprising M199 
medium and Earle’s salts (Life technologies®) supplemented with 2 mM glutamine, 0.2 mM 
sodium pyruvate, 0.1 mM cysteamine, 50 µg/mL gentamycin, 10% v/v FBS (Fetal Bovine 
Serum) and 0.2 µg/mL EGF (Epidermal Growth Factor). 
 120 
2.3. In vitro fertilization 
Semen straws were thawed in a water-bath at 37 °C for 45 s. Straws were wiped down with 70° 
ethanol before opening. The 0.25 mL thawed semen from each straw was layered under 4 mL 
of Sp-TALP capacitation medium (NaCl 114.0 mM; KCl 3.2 mM; NaH2PO4 0.3 mM; Na 
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Lactate 60% 10 mM; MgCl2 0.5 mM; HEPES 10 mM; NaHCO3 25 mM; Na Pyruvate 1 mM 125 
and gentamycin 50 μg/mL; adjusted to pH 7.4) supplemented with 6 mg/mL bovine serum 
albumin (BSA) and 2 µg/mL heparin) in a 15 mL conical tube. Sperm were allowed to swim-
up at 37 °C for 1 h. At the end of the incubation period, the upper layer, containing motile 
sperm, was collected and centrifuged, and the pellet was resuspended in fertilization medium. 
Sperm concentration was measured and 750,000 sperm (or 450,000 when suboptimal sperm 130 
concentration was tested) were injected into a 500 µL droplet of fertilization medium containing 
30 COCs. The composition of in vitro fertilization (IVF) medium was NaCl 114.0 mM; KCl 
3.2 mM; NaH2PO4 0.3 mM; Na Lactate 10.0 mM; CaCl2 2.0 mM; MgCl2 0.5 mM; NaHCO3 
25.0 mM; Minimum Essential Medium (MEM), 50X Amino Acid solution (Life technologies) 
2% vol/vol; 6 mg/mL BSA; 0.2 mM pyruvate; 50 µg/mL gentamycin; 23.5 µg/mL heparin; 135 
20 µM/mL penicillamine; 10 µM hypotaurine and 2 µM/mL epinephrine. Sperm and COCs 
were co-cultured at 38.5 °C under 5% v/v CO2 and saturating humidity for 24 h. 
 
2.4. In vitro embryo culture 
Presumed zygotes were removed from fertilization wells 24 hours after fertilization, vortexed 140 
for 2 min to remove cumulus cells and washed three times by passing through dishes containing 
collection medium. Presumed zygotes were then cultured in 500 µL embryo culture medium in 
4-well plates. Embryo culture medium was mKSOM/aa (modified potassium-supplemented 
simplex optimised medium) supplemented with 20% RD (RPMI-1640 and DMEM, 1:1 
vol/vol), RPMI = Roswell Park Memorial Institute medium-1640 medium (Life technologies, 145 
ref 11879-020) and DMEM = Dulbecco’s Modified Eagle’s Medium (Sigma, ref D6046). 
mKSOM/aa contained NaCl 98.6 mM; KCl 2.5 mM; CaCl2 1.71 mM; KH2PO4 0.35 mM; 
MgSO4 0.2 mM; Na Pyruvate 0.3 mM; Na Lactate 3.0 mM; NaHCO3 25 mM; HEPES 
10.0 mM; 0.27% L-Glutamine (Life technologies 25030-032) + 1.6 % essential  amino acids 
(Life technologies ref 11130-036) and 0.8% non essential amino acids (Life technologies, ref 150 
11140-035); insulin 5 µg/mL; transferrin 5 µg/mL; Na-Selenite 5 ng/mL; EDTA 10 µM, 
dibekacin sulfate 65 µg/mL [29], and covered with 250 µL equilibrated mineral oil. Embryos 
were maintained in culture for 9 days. Post-fertilization, cleavage rates were assessed at 48 h, 
blastocyst formation rate at 7 days, and hatching rate at 9 days, by microscopic observation by 
a trained technician and based on their morphology.  155 
 
2.5.Experimental design 
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In this study, we tested the impact of exposure to recombinant mGX and two other sPLA2s 
(H48Q-mGX and bovine group IB) during the following three phases: in vitro maturation 
(IVM), in vitro fertilization (IVF), in vitro development (IVD) or a combination of IVM and 160 
IVF on embryo production. For IVM, IVF or IVM+IVF treatments, we compared the rates of 
2-cell embryos at 48 h post fertilization and the rates of blastocysts and hatched blastocysts at 
7 and 9 days (D+7 and D+9), respectively, obtained in control conditions or following exposure 
to the different drugs during the period of treatment. For IVD treatment, we compared only the 
rates of blastocysts and hatched blastocysts at D+7 and D+9 (Fig. 1). 165 
 
In details, for IVM treatment, COCs were divided in two groups, the control group was 
processed as explained above and the treated group was incubated in oocyte maturation medium 
containing 200 nM mGX for 24 h. Control and treated COCs were then rinsed twice in oocyte 
maturation medium and introduced into a fertilization droplet containing fertilization medium 170 
(described above) (Fig.1A). For IVF treatment, the control group of gametes (COCs and sperm) 
were introduced in a fertilization droplet containing fertilization medium only and the treated 
group of gametes in a fertilization medium supplemented with 200 nM mGX, for 24 h. Then, 
presumed zygotes were washed and processed as explained in “in vitro embryo culture” 
paragraph (Fig.1A). For IVD treatment, presumed zygotes were produced in control conditions 175 
and then divided in two groups. Control group was cultured in embryo culture medium 
(described above) and treated group in culture medium supplemented with 200 nM mGX for 8 
days. For IVM+IVD treatments, the control group correspond to COC cultured and fertilized 
in control medium whereas treated group correspond to COC cultured and fertilized in 
maturation and fertilization media supplemented with either mGX (200 nM), H48Q-mGX (200 180 
nM) or bGIB (200 nM) (Fig.1A). Finally, we tested mGX effect with a suboptimal 
concentration of sperm for IVF: for the control group, COC were fertilized with 450 000 sperm 
cells (0.9 M/mL) and for treated group, COCs were fertilized with 450 000 sperm cells (0.9 
M/mL) in a fertilization medium supplemented with 200 nM mGX . The effect of mGX addition 
on cleavage, blastocyst and hatching rates were compared between control and treated groups 185 
(Fig. 1B) 
 
 
2.6. Production of recombinant sPLA2 
Mouse group X sPLA2 and its catalytically inactive mutant H48Q-mGX were produced as 190 
described in [30]. Briefly, sPLA2s was produced in E. coli as an inclusion body protein, it was 
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refolded in vitro, and the resulting protein was extensively HPLC-purified. Purified sPLA2 was 
characterized by electrophoresis and mass spectrometry, and specific enzymatic activity was 
measured using radiolabeled E. coli membranes as substrates. Bovine group IB sPLA2 was 
purchased from Sigma Aldrich, and characterized by mass spectrometry to validate the 195 
composition of the purchased lot. 
2.7.Chemicals 
All chemicals were purchased from Sigma Aldrich unless otherwise indicated. 
2.8.Statistical analysis 
Data were treated using R software (version number 3.0.3). The percentage of 2-cell embryos, 200 
blastocysts and hatched blastocysts from control and treated groups were compared based on 
paired t-tests. A probability value of less than 0.05 was considered statistically significant. Data 
are presented as mean ± SEM. 
 
  205 
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3. Results 
3.1 Effects of mGX addition during IVM on cleavage, blastocyst and hatching rates 
Our first objective was to assess whether incubating COCs with 200 nM mGX affected embryo 
production. Exposure to mGX during in vitro oocyte maturation had no impact on the rate of 
initial cleavage and the production of blastocysts (Fig. 2B,C). However, a significant increase 210 
in the yield of hatched blastocysts was observed at D+9 (Fig. 2D). The mean of hatched 
blastocyst percentage increased upon treatment from 39.95 to 67.93%, corresponding to an 70% 
increase of hatched blastocysts (n=9, p=0.00001, paired t-test). Moreover, this increasing rate 
of hatching is associated with a decrease of the rate of non-expanded blastocysts (Fig. 2E). 
3.2 Effects of mGX addition during IVF on cleavage, blastocyst and  hatching rates 215 
Our second objective was to assess whether adding mGX during fertilization process at the time 
of sperm injection impact embryo development. The yields of 2-cell embryos and blastocysts 
were both significantly increased following mGX treatment (Fig. 3BC). The mean of 2-cell 
embryos percentage increased upon treatment from 94.70 to 97.82%, corresponding to an 3.3% 
increase in 2-cell embryos (n=7, p=0.043, paired t-test). This 3.3% increase is close to the 220 
maximal possible increase of 5.6%, corresponding to an increase from 94.7% to 100% of 
fertilized oocytes (Fig. 3B). The percentage of increase of total blastocyst formation induced 
by mGX treatment reached 21.4%, from 30.17 to 36.6% (Fig. 3C). However, the rate of 
blastocyst hatching was not statistically different between the two conditions (Fig.3D). 
Interestingly, the effect of mGX treatment was considerably improved when fertilization was 225 
performed with suboptimal sperm concentrations (sperm concentration was lowered from 1.5 
million/mL to 0.9 million/mL), the percentage of increase, rising from 3.3 to 42.4% for 2-cell 
embryos and from 21.4 to 102.5% for blastocysts, for optimal and suboptimal sperm 
concentration, respectively (Fig. 3EF). 
3.3 Effects of mGX addition during IVD on cleavage, blastocyst and  hatching rates 230 
Finally, we tested the impact of mGX on embryo development by incubating embryos with 
200 nM mGX throughout embryo development (From D+1 to D+9). In these conditions, PLA2 
treatment was deleterious and a significant decrease in blastocyst production and blastocyst 
hatching was recorded (Fig. 4). 
3.4 Effects of mGX addition during IVM and IVF. 235 
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The results presented above show that mGX affects the production of blastocysts differently 
when applied during IVM and IVF steps. We next examined whether application of mGX from 
IMV to IVF produced an additive positive effect, increasing both the rate of blastocyst 
formation and blastocyst hatching. With this protocol, increased 2-cell embryo yields, 
blastocyst formation, and blastocyst hatching rates was observed, demonstrating that the effects 240 
recorded during both steps were additive (Fig. 5). 
3.5 Effects of catalytically-inactive mGX mutant addition during IVM and IVF 
As introduced above, sPLA2 have a dual effect, through enzymatic activity (hydrolyzation) 
and/or through mechanisms requiring their binding to specific membrane receptors. We 
therefore evaluated whether H48Q-mGX, a catalytically inactive mGX mutant, which keeps its 245 
ability to bind to the receptor [31], was able to induce an increase of embryo production 
following treatment during IVM and IVF. In contrast to mGX, the mutant, failed to stimulate 
the production of 2-cell embryos, blastocysts or hatched blastocysts (Fig. 6). 
 
3. Effects of the bovine bGIB sPLA2 addition during IVM and IVF  250 
Recent publications indicate that LysoPhosphatidic Acid (LPA), a byproduct of PLA2 can 
improve in vitro maturation of bovine oocytes and further development [32-34]. To test the 
hypothesis that the effect of mGX could be that it enhances LPA production, we tested a bovine 
sPLA2 known to efficiently produce LPA [35]. Exposure to the bovine group IB sPLA2 (bGIB) 
during oocyte maturation and fertilization steps did not reproduce the effects of exposure to 255 
mGX (Fig.7).  
 
4. Discussion 
The aim of this study was to assess whether sPLA2 improved in vitro production of blastocysts 
in the bovine model. We tested two sPLA2s, the bovine bGIB and the mouse mGX. The mouse 260 
isoform was tested because we had previously shown that mGX increased the production of 
viable embryos in a mouse model [24], whereas all other mouse or human sPLA2s tested failed 
to improve embryo production in this model [36]. We also tested the catalytically inactive 
mutant H48Q-mGX to investigate the mode of action of mGX. In the mouse model, we only 
tested the effect of sPLA2 treatment during the capacitation of sperm on viable embryo 265 
production. In this report, we extended our analysis, with, for the first time, tests of the effect 
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of sPLA2 applied during the three steps required to produce bovine preimplantation embryos in 
vitro: oocyte maturation, fertilization and preimplantation development. Our results showed: 
first, that treatment of COC during oocyte maturation with mGX led to increased hatched 
blastocyst production. This effect is likely due an increase of the developmental competence of 270 
mGX-treated oocyte, since the rate of non-expanded blastocysts is lower when COCS were 
treated (Fig 2E). Second, we showed that treating sperm and oocytes with mGX during 
fertilization step had a specific effect on embryo production. Third, application of mGX from 
oocyte maturation to fertilization steps improve both embryo production and blastocyst 
hatching, which is neither mimicked by bGIB or H48Q-mGX. Finally, we demonstrated that 275 
mGX has a detrimental effect when used during preimplantation development. Moreover, by 
assessing the timing of full blastocyst formation and the ability to hatch, our study allows an 
evaluation of the impact of mGX treatment on embryo quality. Indeed, the kinetics of 
development is reported to be a good indicator of embryo quality for both human and bovine 
embryos [37, 38] along with timing of full blastocyst formation, degree of blastocyst expansion 280 
and the ability to hatch [39, 40].  
4.1.PLA2 and oocyte maturation 
Lipid metabolites are important for oocyte maturation, in particular through the production of 
LPA. LPA was shown to have a positive effect on oocyte maturation and subsequent 
fertilization competence of oocytes in rodent, bovine and porcine species [32, 41, 42] due to 285 
changes observed in cumulus cells [33, 43]. LPA synthesis first requires activation of 
phospholipase D (PLD) [44], which converts phosphatidylcholine to phosphatidic acid (PA), 
and then requires activation of a PLA2 to hydrolyze the sn-2 ester bond of PA, producing LPA. 
Numerous PLA2 have been described as involved in this process, including members of the 
iPLA2, cPLA2 and sPLA2 subfamilies. Among sPLA2, several groups can convert PA into LPA. 290 
Based on an in vitro assay measuring LPA production by different mouse and human sPLA2 
from a mixture of different phospholipids, mouse and human group X and IB sPLA2 were 
reported to display similar potency [35]. Although both groups X and IB produce similar levels 
of LPA, here, we demonstrated that only mGX improves oocyte competence. This result 
strongly suggests that the effect of PLA2 does not rely on LPA production. Group X sPLA2s 295 
are also known to release arachidonic acid from mammalian cells more effectively than other 
PLA2. Arachidonate is the primary substrate for prostaglandin production, and prostaglandin 
E2 is a key factor regulating mammalian oocyte maturation [45]. Therefore, treatment of COC 
by mGX probably promotes arachidonate release, triggering prostaglandin production which 
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positively regulates oocyte maturation. The fact that the enzymatically-inactive H48Q-mGX 300 
mutant has no effect supports this hypothesis. Oocyte quality is the cornerstone of reproductive 
success, both in vitro and in vivo, and enhanced oocyte maturation in the presence of mGX will 
have a positive impact on embryo development, in particular in bovine species where embryo 
genome activation is delayed until day 4. 
4.2. Impact of gametes treatment on embryo production 305 
The discovery of mGX’s action on the production of viable embryos was first described in the 
mouse model, and its action was shown to require enzymatic activity [24]. In this report, we 
show that mGX is also potent in the bovine model. In the mouse model, only sperm was treated 
and increased 2-cell embryo production. In the bovine model, both sperm and oocytes were 
simultaneously treated during the fertilization step and this treatment improved rates of both 2-310 
cell embryo and blastocyst production, obtained with suboptimal and optimal sperm 
concentration. In suboptimal conditions, mGX is more effective, approaching the efficiency for 
2-cell embryos observed in the mouse model. In optimal condition, the increase in the yield of 
blastocyst embryos is not due to the generation of increased numbers of 2-cell embryos, because 
the increase in 2-cell embryos is just 3.3%, compared to an increase in blastocysts of 21.4%. 315 
Moreover, we show that bGIB, another sPLA2 has no effect. So far, thus mGX is the only 
sPLA2 shown to improve sperm’s ability to produce viable embryos. We therefore confirm that 
mGX has exceptional specificity [36]. Importantly, our results demonstrate that mGX is potent 
on at least two species, and that its efficacy is not restricted to the mouse model, even though it 
is a mouse isoform. Finally, the enzymatically-inactive H48Q-mGX mutant has no effect on 320 
bovine sperm, confirming that the effect observed with mGX requires production of lipid 
metabolites. 
4.3. PLA2 and embryo development 
The molecular mechanism behind the inhibition of development of preimplantation embryos 
was not explored here, but we can speculate that this effect may be due to overproduction of 325 
arachidonic acid and excessive stimulation of the prostaglandin cascade. Indeed, 
preimplantation embryos have the enzymes needed to synthesize prostaglandin from 
arachidonic acid [46], and prostaglandins are known to control the growth factor-induced 
mitogenic pathway [47]. Therefore, an imbalance in this pathway could lead to developmental 
defects. 330 
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4.4. Conclusion 
 We have demonstrated for the first time that treating bovine gametes with sPLA2 during either 
in vitro oocyte maturation or/and fertilization periods has a beneficial effect on blastocyst 
production, improving both their quantity and quality. In contrast, treating embryos during pre-
implantation development hampers their development. The enzymatic properties of sPLA2 are 335 
crucial, since beneficial effects were observed with mouse group X sPLA2 whereas bovine 
group IB sPLA2 is embryo-toxic, hampering the blastocyst hatching (Fig. 7). Therefore, 
efficacy of mGX is not restricted to the mouse model and confirms the potential of mGX as a 
“pro fertility drug” for mammalian reproduction. 
 340 
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Fig. legends 
 
Fig. 1. Experimental protocol showing the different periods of treatment (IVM, IVF and 
IVM+IVF) and the timing of assessment of in vitro embryos production.  355 
(A) Mouse group X (mGX) sPLA2 was applied either during in vitro maturation (IVM) of COC 
for 24 h, in vitro fertilization (IVF) for 24 h or in vitro development (IVD) for 8 days (from day 
1 (D+1) to day 9 (D+9)). Mouse group X and two other sPLA2s were also applied during a 
combination of IVM and IVF for 48 h. At day 0 (D0), mature COC were fertilized and incubated 
together with sperm for 24 h. At day 1 (D+1) presumed zygote were transferred to culture 360 
medium and then cultured up to day 9 (D+9). (B) Two-cell embryos were assessed at day 2 
(D+2), blastocyst at day 7 (D+7) and hatched blastocyst at day 9 (D+9), as indicated.  
 
Fig. 2. mGX-sPLA2 enhances blastocyst expansion and hatching when applied during in vitro 
maturation (IVM) of oocytes. 365 
(A) mGX (200 nM) was applied during the IVM stage only. (B) Yield of 2-cell embryos on day 
2 for COC incubated in control and mGX media versus total number of matured oocytes. (C) 
Yield of blastocysts on day 7. (D) Yield of hatched blastocysts on day 9. (E) Proportions of 
non-expanded, expanded and hatched embryos on day 9. n = 9 replicates. Range of oocytes 
number per condition: 215-225. Statistical differences were assessed using a paired t-test. 370 
 
Fig. 3. mGX-sPLA2 enhances 2-cell embryo and blastocyst production when applied during in 
vitro fertilization (IVF). 
(A) mGX (200 nM) was applied during the IVF step only. (B) Yield of 2-cell embryos on day 
2 for gametes incubated in control and mGX-supplemented media. (C) Yield of blastocysts on 375 
day 7. (D) Yield of hatched blastocysts on day 9. n = 7 replicates. Total number of oocytes: 195 
± 5/condition (mean ± SEM). Statistical differences were assessed using a paired t-test. (E, F) 
mGX effect during IVF is improved when oocytes are fertilized with a suboptimal sperm 
concentration (sperm concentration was lowered from 1.5 million/mL to 0.9 million/mL). 
Marked improvement is measured for production of 2-cell embryos (E) and blastocysts (F). n 380 
14 
 
= 4 replicates. Range of oocytes number per condition: 165-175. Statistical differences were 
assessed using a paired t-test. 
 
Fig. 4. mGX-sPLA2 applied during the in vitro development (IVD) step reduces embryo 
production. 385 
(A) mGX (200 nM) was applied during the IVD step only. (B) Yield of 2-cell embryos on day 
2 for embryos incubated in control and mGX-supplemented media. (C) Yield of blastocysts on 
day 7. (D) Yield of hatched blastocysts on day 9. n = 3 replicates. Range of oocytes number per 
condition: 110-120. Statistical differences were assessed using a paired t-test. 
 390 
Fig. 5. mGX-sPLA2 applied from IVM to IVF stages improves both embryo production and 
blastocyst hatching. 
(A) mGX (200 nM) was applied from IVM to IVF steps. (B) Yield of 2-cell embryos on day 2 
for gametes/embryos incubated in control and mGX-supplemented media. (C) Yield of 
blastocysts on day 7. (D) Yield of hatched blastocysts on day 9. n = 3 replicates. Range of 395 
oocytes number per condition: 65-75. Statistical differences were assessed using a paired t-test. 
 
Fig. 6. Enzymatically-inactive H48Q-mGX mutant fails to enhance in vitro embryo production. 
(A) The enzymatically-inactive H48Q-mGX mutant (200 nM) was applied from IVM to IVF 
steps. (B) Yield of 2-cell embryos on day 2 for gametes/embryos incubated in control and 400 
H48Q-mGX-containing media. (C) Yield of blastocysts on day 7. (D) Yield of hatched 
blastocysts on day 9. n = 6 replicates. Range of oocytes number per condition: 200-270. 
Statistical differences were assessed using a paired t-test. 
 
Fig. 7. Bovine group IB (bGIB) sPLA2 applied from IVM to IVF stages adversely impacts in 405 
vitro embryo production rates. 
(A) bGIB (200 nM) was applied from IVM to IVF steps. (B) Yield of 2-cell embryos on day 2 
for gametes/embryos incubated in control or bGIB-supplemented media. (C) Yield of 
15 
 
blastocysts on day 7. (D) Yield of hatched blastocysts on day 9. n = 3 replicates. Range of 
oocytes number per condition: 65-75. Statistical differences were assessed using a paired t-test. 410 
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